IS A CURE IN R/R LYMPHOMA ON THE HORIZON?
Insights from ASH
Plenary room, Schweitzer Auditorium
Palais de la Musique et des Congrès,
Place de Bordeaux, 67000,
Strasbourg, France
Our symposium
Join Prof Roch Houot, Dr. Victoria Campbell and Dr. Abdulwahab Albabtain as they look at answering this important question: are we heading towards a potential cure in relapsed/refractory lymphomas with CAR T?
They will discuss the latest data presented at ASH 2024, including long-term follow-up data and real-world evidence that demonstrates the transformative impact of CAR T and how management strategies have evolved, leading to better outcomes for patients.
Join us on:
Friday 7th February, 13:00 PM - 13:45 PM CET in the Schweitzer Auditorium.
Chair: Professor Roch Houot
University Hospital of Rennes,
Rennes, France
13:00 PM - 13:05 PM
Welcome and introduction
Chair: Professor Roch Houot
University Hospital of Rennes,
Rennes, France
13:05 PM - 13:15 PM
CAR T in practice: insights and implications from real-world data
Dr Victoria Campbell
Western General Hospital,
Edinburgh, UK
13:15 PM - 13:25 PM
Optimising patient outcomes in CAR T care
Dr Abdulwahab Albabtain
King Faisal Specialist Hospital and Research Centre,
Riyadh, Saudi Arabia
13:25 PM - 13:35 PM
Are we moving towards a cure in R/R lymphoma?
All, facilitated by Chair:
Professor Roch Houot
13:35 PM - 13:45 PM
Wrap-up and Q&A
Abbreviations:
ASH, American Society of Hematology; CAR T, chimeric antigen receptor T cell; CPD, Continuing Professional Development;Q&A, question and answer; R/R, relapsed/refractory. This event has been submitted for CPD accreditation.
Resources
MEET THE FACULTY
Prof. Roch Houot
Head of the Haematology Department, University Hospital of Rennes (CHU Rennes)
Roch Houot is Professor of Haematology and Head of the Haematology Department at the University Hospital of Rennes (CHU Rennes) in France. Following studies at the Universities of Lyon, Rennes, and Stanford (USA), he has held his current position since 2021. Prof. Houot’s primary research interest is the development of new immunotherapies for the treatment of lymphoma (primarily immunomodulatory antibodies and CAR T-cells).
Prof. Houot has lectured and published widely having authored a number of books and over 200 peer-reviewed publications. He has been the Principal Investigator of several clinical trials, including ALYCANTE (the first French academic trial with CAR T-cells). He is the National Coordinator of the DESCAR-T Registry and of the UNITC Consortium (National consortium to coordinate strategic and operational research on CAR T-cells and other innovative gene therapies in oncology). Prof. Houot is also a co-founder of the French Society for Cancer Immunotherapy (FITC) and a board member of the Lymphoma Study Association (LYSA).
Dr Victoria Campbell
Consultant Haematologist, NHS Lothian.
Dr Victoria Campbell is a Consultant Haematologist in NHS Lothian. After graduating from Imperial College she rotated through a number of London teaching hospital before moving to Scotland. As a Consultant she has worked in both District General and Teaching hospitals, affording her an understanding of the unique pressures within each care system.
She is currently the Transplant Programme Director for S E Scotland, the largest autologous only centre in the UK, and set up their CART centre, the first within an autologous only centre within the UK. She has led the team to challenge current care models, setting up ambulatory and hub and spoke delivery models. She is the AT(1)MP lead for the region. Alongside this she leads the Haematology trials unit including establishing the Early Phase unit; she is PI on >10 studies and CI on a Phase II study. and the regions diagnostic service. She is passionate about improving patient care.
Dr. Abdulwahab A. Albabtain
Consultant haematologist, King Faisal Specialist Hospital
Dr. Abdulwahab A. Albabtain is a consultant haematologist at King Faisal Specialist Hospital and Research Centre. He received his MBBS from the King Saud University of Riyadh, Saudi Arabia, and completed his residency in internal medicine and fellowship in heamatology/oncology at Wayne State University of Detroit, Michigan, USA. He completed a clinical fellowship in Bone and Marrow Transplantation/ Cancer Cellular Therapy (including CART Cell Therapy) at Stanford University Hospital School of Medicine.
Currently, Dr. Albabtain directs the lymphoma and Plasma Cell Disorders program and co-chairs the CAR T-Cell Program Oversight Committee. He has authored and co-authored numerous publications in peer-reviewed journals, including Frontiers in Oncology and the International Journal of Hematology and Oncology. Additionally, he serves as the primary investigator for the Lymphoma Database/Registry of the Saudi Arabian population.
